

POLYDEX PHARMACEUTICALS LIMITED

QUARTERLY DISCLOSURE REPORT

OCTOBER 31, 2017

UNAUDITED

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
OCTOBER 31, 2017
UNAUDITED

INDEX

ITEM I	Name of Issuer	Page	3
ITEM II	Share Structure	Page	3
ITEM III	Consolidated Financial Statements		
	Interim Financial Statements	Page	4-9
	Notes to Interim Financial Statements	Page	10-18
ITEM IV	Management Discussion and Analysis	Page	19-27
ITEM V	Legal Proceedings	Page	28
ITEM VI	Defaults Upon Senior Securities	Page	28
ITEM VII	Other Information	Page	28
ITEM VIII	Exhibits	Page	28
ITEM IX	Certifications	Page	29-30

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
OCTOBER 31, 2017
UNAUDITED

ITEM I NAME OF ISSUER

Polydex Pharmaceuticals Limited
421 Comstock Road
Toronto, Ontario, Canada
M1L 2H5
Tel: (416) 755-2231
Fax: (416) 755-0334
Web: www.polydex.com

ITEM II SHARES OUTSTANDING

Preferred Stock – Class A

(i)	Period end date	October 31, 2017
(ii)	Authorized	100,000 shares at \$0.10 each
(iii)	Issued and outstanding	None
(iv)	Freely tradable shares (public float)	None
(v)	Number of shareholders of record	None

Preferred Stock – Class B

(i)	Period end date	October 31, 2017
(ii)	Authorized	899,400 shares at \$0.0167 each
(iii)	Issued and outstanding	899,400 shares
(iv)	Freely tradable shares (public float)	None
(v)	Number of shareholders of record	1

Common Stock

(i)	Period end date	October 31, 2017
(ii)	Authorized	10,000,000 shares
(iii)	Issued and outstanding	3,399,978 shares
(iv)	Freely tradable shares (public float)	2,386,525
(v)	Number of shareholders of record	223

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
OCTOBER 31, 2017
UNAUDITED

ITEM III INTERIM FINANCIAL STATEMENTS

CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

TABLE OF CONTENTS

Consolidated Balance Sheets October 31, 2017 and January 31, 2017 (Unaudited)	5-6
Consolidated Statements of Operations and Comprehensive Income Three and Nine months ended October 31, 2017 and 2016 (Unaudited)	7
Consolidated Statements of Shareholders' Equity Nine months ended October 31, 2017 and 2016 (Unaudited)	8
Consolidated Statements of Cash Flows Nine months ended October 31, 2017 and 2016 (Unaudited)	9
Notes to Consolidated Financial Statements (Unaudited)	10-18

POLYDEX PHARMACEUTICALS LIMITED
CONSOLIDATED BALANCE SHEETS
OCTOBER 31, 2017
UNAUDITED

(Expressed in United States dollars)

	October 31	January 31
	2017	2017
	(Unaudited)	(Unaudited)
Assets		
Current assets:		
Cash	\$557,182	\$653,214
Investments available for sale (note 3)	641,223	620,578
Trade accounts receivable	1,272,597	1,103,759
Inventories		
Finished goods	668,073	852,704
Work in progress	52,121	69,567
Raw materials	<u>330,941</u>	<u>235,303</u>
	1,051,135	1,157,574
Prepaid expenses and other current assets	31,185	68,630
Total current assets	3,553,322	3,603,755
Property, plant and equipment, net	3,335,272	3,058,960
Deferred taxes (note 9)	--	21,986
Due from estate of former shareholder	20,903	20,903
	<u>\$6,909,497</u>	<u>\$6,705,604</u>

See accompanying notes.

POLYDEX PHARMACEUTICALS LIMITED
CONSOLIDATED BALANCE SHEETS
OCTOBER 31, 2017
UNAUDITED

(Expressed in United States dollars)

	October 31 2017	January 31 2017
	(Unaudited)	(Unaudited)
Liabilities and Shareholders' Equity		
Current liabilities:		
Accounts payable	\$420,970	\$443,717
Accrued liabilities	260,778	426,582
Income taxes payable	1,643	3,350
Other loans and advances (note 4)	138,625	151,225
Current portion of long-term debt	46,639	44,157
Current portion of capital lease obligations	16,467	38,309
Current portion of due to shareholder	36,000	36,000
Total current liabilities	921,122	1,143,340
Long-term debt (note 5a)	113,627	144,041
Capital lease obligations (note 5b)	11,283	16,889
Due to shareholder	342,635	360,617
	467,545	521,547
Total liabilities	1,388,667	1,664,887
Commitments and contingencies (note 6)		
Susequent events (note 7)		
Shareholders' equity:		
Capital stock		
Authorized:		
100,000 Class A preferred shares of \$0.10 each		
899,400 Class B preferred shares of \$0.0167 each		
10,000,000 common shares of \$0.0167 each		
Issued and outstanding:		
899,400 Class B preferred shares (January 31, 2017 - 899,400)	15,010	15,010
3,399,478 common shares (January 31, 2017 - 3,399,478)	56,649	56,649
Contributed surplus	23,801,359	23,801,359
Deficit	(18,857,600)	(19,220,395)
Accumulated other comprehensive income	505,412	388,094
	5,520,830	5,040,717
	\$6,909,497	\$6,705,604

See accompanying notes.

POLYDEX PHARMACEUTICALS LIMITED
CONSOLIDATED STATEMENTS OF OPERATIONS
OCTOBER 31, 2017
UNAUDITED

(Expressed in United States dollars)

	Three Months Ended October 31 2017 (Unaudited)	Three Months Ended October 31 2016 (Unaudited)	Nine Months Ended October 31 2017 (Unaudited)	Nine Months Ended October 31 2016 (Unaudited)
Sales	\$1,434,587	\$1,447,510	3,969,294	4,642,861
Cost of goods sold	1,098,556	1,034,805	3,047,732	3,240,601
Gross profit	336,031	412,705	921,562	1,402,260
Expenses				
General and administrative	147,141	179,327	443,270	531,320
Selling and promotion	11,593	12,573	37,336	43,439
Interest expense, net	8,331	9,235	25,239	29,015
Depreciation	1,977	1,696	5,709	6,092
Research and development	--	--	--	600
Foreign exchange (gain) loss	(65,148)	(91,322)	18,779	20,178
Interest and other income	(2,224)	(455)	(5,010)	(1,647)
Total expenses	101,670	111,054	525,323	628,997
Income before income taxes	234,361	301,651	396,239	773,263
Provision for income taxes (note 9)				
Current	217	1,393	11,504	4,936
Deferred	413	56,002	21,940	167,327
	630	57,395	33,444	172,263
Net income for the period	233,731	244,256	362,795	601,000
Unrealized gain (loss) on investments	(668)	1,668	(3,198)	959
Currency translation adjustment	(45,315)	(166,734)	120,516	188,299
Comprehensive income for the period	\$187,748	\$79,190	\$480,113	\$790,258
Per share information:				
Earnings per common share:				
Basic	0.07	0.07	0.11	0.18
Diluted	0.07	0.07	0.10	0.17
Weighted average number of common shares used compute net income per share for the period:				
Basic	3,399,978	3,380,478	3,399,978	3,380,478
Diluted	3,486,590	3,518,681	3,501,355	3,530,419

See accompanying notes.

POLYDEX PHARMACEUTICALS LIMITED
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
OCTOBER 31, 2017
UNAUDITED

(Expressed in United States dollars)

	Six Months Ended October 31 2017	Six Months Ended October 31 2016
	(Unaudited)	(Unaudited)
Preferred Shares:		
Balance, beginning and end of period	\$15,010	\$15,010
Common Shares:		
Balance, beginning and end of period	\$56,649	\$56,323
Contributed Surplus:		
Balance, beginning and end of period	\$23,801,359	\$23,792,519
Deficit:		
Balance, beginning of period	(\$19,220,395)	(\$19,889,654)
Net profit for the period	362,795	601,000
Balance, end of period	(\$18,857,600)	(\$19,288,654)
Accumulated Other Comprehensive Income:		
Balance, beginning of period	\$388,094	\$13,540
Unrealized gain on investments available for sale	(3,198)	959
Currency translation adjustment for the period	120,516	188,299
Balance, end of period	\$505,412	\$202,798

See accompanying notes.

POLYDEX PHARMACEUTICALS LIMITED
CONSOLIDATED STATEMENTS OF CASH FLOWS
OCTOBER 31, 2017
UNAUDITED

(Expressed in United States dollars)

	Nine Months Ended October 31 2017	Nine Months Ended October 31 2016
	(Unaudited)	(Unaudited)
Cash provided by (used in):		
Operating activities:		
Net profit for the period	\$362,795	\$601,000
Add (deduct) items not affecting cash:		
Depreciation and amortization	181,644	161,607
Deferred income taxes (note 9)	21,940	167,327
Net change in non-cash working capital balances related to operations	(179,183)	80,837
Cash provided by operating activities	387,196	1,010,771
Investing activities:		
Additions to property, plant and equipment	(353,280)	(260,214)
Proceeds (Acquisition) of investments available for sale	(4,935)	(230,863)
Cash used in investing activities	(358,215)	(491,077)
Financing activities:		
Repayment of long-term debt	(32,877)	(31,420)
Proceeds (Repayment) of capital lease obligations, net	(28,258)	(24,921)
Decrease in due to shareholder	(17,979)	(18,652)
Cash used in financing activities	(79,114)	(74,993)
Effect of exchange rate changes	(45,899)	19,103
Net increase in cash and cash equivalents	(96,032)	463,804
Cash, beginning of year	653,214	942,555
Cash, end of period	\$557,182	\$1,406,359

See accompanying notes.

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
OCTOBER 31, 2017
UNAUDITED

ITEM III NOTES TO INTERIM FINANCIAL STATEMENTS

1. Basis of Presentation:

The information contained in the interim consolidated financial statements is condensed from that which would appear in annual consolidated financial statements. The interim consolidated financial statements included herein should be read in conjunction with the unaudited financial statements, and notes thereto, and other financial information contained in the 2017 Annual Report for the fiscal year ended January 31, 2017 as found on the Polydex Pharmaceuticals Limited (the “Company”) website, www.polydex.com. The unaudited interim consolidated financial statements as of October 31, 2017 and 2016 include all normal recurring adjustments which management considers necessary for a fair presentation. The results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the entire fiscal year. The interim consolidated financial statements include the accounts and transactions of the Company and its majority owned subsidiaries in which the Company has equal to or more than a 50% ownership interest and exercises control.

Management has reviewed subsequent events, and there were no material subsequent events since December 15, 2017 that would require recognition or note disclosures in these financial statements.

2. Significant Accounting Policies:

Basis of consolidation

The interim consolidated financial statements include the accounts of the Company and its subsidiaries. All inter-company accounts and transactions have been eliminated on consolidation.

Cash and cash equivalents

Cash and cash equivalents include cash and short-term deposits with maturities of less than three months at the date of purchase.

Use of estimates

The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant accounting estimates relate to the allowance for doubtful accounts, depreciation and amortization rates, and asset impairment charges.

Inventories

Inventories of raw materials are stated at the lower of cost and net realizable value, cost being determined on a first-in, first-out basis. Work-in-process and finished goods are valued at the lower of cost and net

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
OCTOBER 31, 2017
UNAUDITED

realizable value, and include the cost of raw materials, direct labor and fixed and variable overhead expenses.

Investments available for sale

Investments available for sale consist of Canadian fixed income mutual funds, and are stated at fair market value based on quoted market prices. Interest income is included in other income in the consolidated statement of operations as it is earned. Changes in market values during the holding period are reported as unrealized gain (loss) on investments available for sale and are included in other comprehensive income (loss). Realized gains (losses) are reclassified from accumulated other comprehensive income (loss) on a specific item basis when the security is sold or matured.

Property, plant and equipment and patents and intangible assets

Property, plant and equipment are recorded at cost less accumulated depreciation. Depreciation is provided on a straight-line basis over the estimated useful lives of the assets as follows:

Buildings 15 years

Machinery and equipment 3 to 10 years

Patents and intangible assets are recorded at cost and are amortized on a straight-line basis over their estimated useful lives of ten years. Intangible assets consist of intellectual property, government licenses and government license applications.

Useful life is the period over which the asset is expected to contribute to the Company's future cash flows. The Company reviews the recoverability of its long-lived assets annually when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on the Company's ability to recover the carrying value of the asset from the expected future pre-tax cash flows of the related operations. If these cash flows are less than the carrying value of such asset, an impairment loss is recognized for the difference between estimated fair value and carrying value.

Costs related to plant refurbishments and equipment upgrades that represent improvements to existing facilities are capitalized. Costs related to repair and maintenance of buildings and equipment are expensed. The Company has no major planned maintenance activity.

Revenue recognition

Revenue results from sales of bulk manufactured products. Revenue is recognized when title and risk of ownership of products pass to the customer. Title and risk of ownership pass to the customer pursuant to the applicable sales contract, either upon shipment of product or upon receipt by the customer.

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
OCTOBER 31, 2017
UNAUDITED

Product sold in bulk quantities is tested, prior to release for shipment, to ensure that it meets customer specifications, and in many cases, customers receive samples for their own testing. Approval is obtained from the customer prior to shipping. Further purchases by a customer of a bulk product with the same specifications do not require approvals. Returns of bulk product are rare and generally are not accepted.

Comprehensive income

The Company discloses comprehensive income in their financial statements. In addition to items included in net income, comprehensive income includes items currently charged or credited directly to shareholders' equity, such as foreign currency translation adjustments.

Shipping and handling costs

Shipping and handling costs incurred by the Company for shipment of products to customers are included in cost of goods sold.

Research and development

Research and development costs are expensed as incurred and are stated net of investment tax credits earned.

Foreign currency translation

The functional currency of the Company's Canadian operations has been determined to be the Canadian dollar. All asset and liability accounts of the Company except capital stock have been translated into United States dollars using the current exchange rates at the interim consolidated balance sheet dates. Capital stock is recorded at historical rates. Revenue and expense items are translated using the average exchange rates for the year. The resulting gains and losses have been reported separately as accumulated other comprehensive income within shareholders' equity.

Derivative financial instruments

The Company's Canadian subsidiary enters into foreign exchange contracts from time to time, to manage exposure to currency rate fluctuations related to expected future cash flows. The Company does not engage in speculative trading of derivative financial instruments. The foreign exchange contracts are not designated as hedging instruments, and as a result all foreign exchange contracts are marked to market and the resulting gains and losses are recorded in the consolidated statements of operations in each reporting period. Unrealized gains and losses are included in accrued liabilities in the consolidated balance sheets and in net change in non-cash working capital balances related to operations in the consolidated statements of cash flows. For the three months and nine months ended October 31, 2017 the Company has not entered into any derivative financial instruments.

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
OCTOBER 31, 2017
UNAUDITED

Stock options

The Company uses the fair value accounting to apply recognition provisions to its employee stock options granted, modified or settled. Compensation expense is recorded at the date stock options are granted. The amount of compensation expense is determined by estimating the fair value of the options granted using the Black-Scholes option pricing model.

Income taxes

The Company accounts for income taxes by recognizing deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statement or tax returns. Deferred income taxes are provided for using the liability method. Under the liability method, deferred income taxes are recognized for all significant temporary differences between the tax and financial statement bases of assets and liabilities.

Effects of changes in enacted tax laws on deferred tax assets and liabilities are reflected as adjustments to tax expense in the period of enactment. Deferred tax assets may be reduced if deemed necessary based on a judgmental assessment of available evidence, by a valuation allowance for the amount of any tax benefits which are more likely, based on current circumstances, not expected to be realized.

Income (loss) per common share

Basic earnings per common share is computed using the weighted average number of common shares outstanding of 3,399,978 for the three and nine months ended October 31, 2017, as compared to 3,380,478 for the three and nine months ended October 31, 2016. Diluted earnings per common share is computed using the weighted average number of common shares outstanding adjusted for the incremental shares, using the treasury stock method, attributed to outstanding options to purchase common stock. Options to purchase common shares of 101,377 were included in the computation of year to date diluted earnings per share as at October 31, 2017, and 86,612 incremental shares were included for the three months ended October 31, 2017. Options to purchase common shares of 149,941 were included in the computation of year to date diluted earnings per share as at October 31, 2016, and 138,203 incremental shares were included for the three months ended October 31, 2016.

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
OCTOBER 31, 2017
UNAUDITED

3. Investments Available for sale

Investments available for sale consist of the following:

	October 31 2017 \$	January 31 2017 \$
TD short term bond fund consisting of Canadian government and Corporate bonds maturing in the next 1-5 years, currently yielding 2.41%	315,702	307,312
5 year global fixed income fund class A, with an average maturity of 3.95 years and a yield to maturity of 1.80%	325,521	313,266
	641,223	620,578

Investments available for sale are stated at fair value, based on quoted market prices. The Company expects that the investments available for sale may be used for working capital for fiscal 2018 and onwards. Accordingly the investments available for sale were classified as part of current assets as at October 31, 2017. An unrealized loss of \$3,198 has been included in accumulated other comprehensive income

4. Other loans and advances:

Other loans and advances consist of the following:

	October 31 2017 \$	January 31 2017 \$
Customer advance	113,625	126,225
Customer deposit	25,000	25,000
	138,625	151,225

The advance and deposit from customers are non-interest bearing, unsecured, and are repayable on demand.

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
OCTOBER 31, 2017
UNAUDITED

5. Long term debt obligations:

[a] Bank term loan consists of the following:

	October 31 2017	January 31 2017
	\$	\$
Bank term loan payable in monthly installments of Cdn \$5,547 (U.S. \$4,401) principal and interest at the Canadian bank's fixed rate of 4.20%	160,266	188,198
Less: current portion	46,639	44,157
	113,627	144,041

The bank term loan was arranged in January 2016 for 60 months at a fixed rate of prime plus 1.5% (2017 and 2016- 4.20%). The company also obtained an operating loan facility of Cdn \$300,000 (USD – \$238,000) for working capital purposes, of which none was utilized at October 31, 2017 and January 31, 2017. This Canadian operating facility bears interest at the Canadian banks' prime lending rate plus 3.00% (2017-4.70%; 2016–4.50%) (See also note 7). Bank indebtedness is collateralized by a general security agreement over the Company's assets and a collateral mortgage of Cdn \$500,000 (USD – \$396,668) on the company building at its Toronto location.

Interest expense for the nine months ended October 31, 2017 for the bank loan was \$5,499 (2016 - \$6,726).

Principal repayments on the bank loan are as follows:

	\$
2018	46,638
2019	48,750
2020	50,955
2021	13,923
	160,266

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
OCTOBER 31, 2017
UNAUDITED

[b] Capital lease obligations consist of the following:

	October 31 2017	January 31 2017
	\$	\$
Obligation (Cdn. \$19,100) under a capital lease, repayable in quarterly installments of \$1,283 bearing interest at 9.42% and maturing in fiscal 2021	15,153	17,249
Obligation (Cdn. \$15,879) under a capital lease, repayable in monthly installments of \$3,240 bearing interest at 12.67% and maturing in fiscal 2018	12,597	37,949
Less current portion	(16,467)	(38,309)
	11,283	16,889

Future minimum annual lease payments on the capital lease obligations including interest are as follows:

	\$
2018	18,095
2019	5,132
2020	5,132
2021	2,566
Total minimum lease payments	30,925
Less amount representing imputed interest	3,075
	27,750

Interest expense for the 9 months ended October 31, 2017 for capital lease obligations was \$5,522 (2016 - \$5,763)

6. Commitments and Contingencies:

A subsidiary of the Company, Chemdex, Inc, has a supply agreement with an existing customer to supply raw materials for an existing product. The agreement is for a period of ten years, renewable for another ten years, and provides the customer with exclusive rights to these raw materials in the United States. The agreement also committed the Company to provide materials and advice for the development of a new product, which was completed in fiscal 2016. Once this product is registered in the United States the Company will receive a payment for \$250,000, and will provide the raw materials required.

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
OCTOBER 31, 2017
UNAUDITED

The Company's subsidiary, Dextran Products Limited has committed to purchase approximately \$180,000 of partially finished product from a contract manufacturer.

There were no other material commitments or contingencies outstanding as at October 31, 2017.

7. Subsequent Events

Subsequent to January 31, 2017 and with the approval of the Company's directors, the process of amalgamation of Polydex Pharmaceuticals Limited with its subsidiaries Dextran Products Limited and Polydex Chemicals (Canada) Limited was initiated. To facilitate this amalgamation Polydex Pharmaceuticals Limited and Polydex Chemicals (Canada) Limited were continued as Ontario corporations. The amalgamation took place on May 1, 2017.

In December of 2017 the Company arranged to utilize its approved limit with its Canadian bank to borrow Cdn \$250,000 (USD \$197,000) to finance the purchase of additional capital equipment and building improvements.

8. Stock-based Employee Compensation:

The Company maintains an incentive share option plan for management personnel for options to purchase up to 729,668 common shares. The Company also issues options to certain consultants for services provided to the Company.

All options granted have terms of five years and vest immediately. At October 31, 2017, the Company had 244,000 options outstanding at exercise prices ranging from \$0.31 to \$1.80 and a weighted average exercise price of \$0.89. The options expire on dates between January 31, 2018 and January 31, 2022, and entitle the holder of an option to acquire one common share of the Company.

The Company uses the fair value method to account for awards of stock-based employee compensation. No stock-based employee compensation expense was recorded during the period from February 1, 2017 to October 31, 2017, because there were no options granted during this period. Similarly, no stock-based employee compensation expense was recorded during the period from February 1, 2016 to October 31, 2016, because there were no options granted during that period.

8. Provision for Income Taxes

The Company's current income tax provision relates to income taxes owing at its former subsidiary Dextran Products Limited. The deferred tax provision consists of expensing the remaining deferred tax asset since it is fully utilized during the 9 months ended October 31, 2017.

POLYDEX PHARMACEUTICALS LIMITED
 QUARTERLY REPORT
 OCTOBER 31, 2017
 UNAUDITED

9. Segmented Information:

Total revenue by significant customer:

	Nine Months Ended October 31, 2017	Nine Months Ended October 31, 2016
Customer A	\$ 691,920	\$ 351,925
Customer B	561,850	452,899
Customer C	452,100	225,000
Customer D	346,170	728,111
Customer E	310,350	301,910
Customer F	245,760	307,200
Customer G	85,683	801,754
	\$ 2,693,833	\$ 3,168,800

Sales by geographic destination:

	Nine Months Ended October 31, 2017	Nine Months Ended October 31, 2016
United States	\$ 1,483,543	\$ 1,782,983
Europe	1,217,327	1,747,676
Canada	698,654	373,297
Other	449,371	624,405
Pacific Rim	120,400	114,500
	\$ 3,969,294	\$ 4,642,861

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
OCTOBER 31, 2017
UNAUDITED

ITEM IV MANAGEMENT DISCUSSION AND ANALYSIS

The Company's fiscal year ends on January 31st of each year. In this report, fiscal year 2017 refers to the Company's fiscal year ended January 31, 2017. The following discussion should be read in conjunction with the October 31, 2017 interim consolidated financial statements and notes thereto included elsewhere in this report. Operating results for the nine months ended October 31, 2017 are not necessarily indicative of the results that may be expected for the fiscal year ending January 31, 2018. For further information, refer to the Polydex Pharmaceuticals Limited Annual Report on our website www.polydex.com for the fiscal year ended January 31, 2017. All amounts are in United States dollars, unless otherwise denoted.

Overview

The Company is engaged in the manufacture of bulk pharmaceutical intermediates for the worldwide veterinary pharmaceutical industry and also the manufacture and marketing of biotechnology-based products for the human pharmaceutical market. The Company conducts its business operations through its wholly-owned subsidiary Chemdex, Inc. and its corporate division operating as Dextran Products. (On May 1, 2017 Dextran Products Limited and Polydex Chemicals (Canada) Limited were amalgamated into the parent company Polydex Pharmaceuticals Limited).

The manufacture and sale of bulk quantities of dextran and derivative products for sale to large pharmaceutical companies throughout the world is conducted through Dextran Products in Canada. Chemdex in the United States provides ferric hydroxide and hydrogenated dextran to Sparhawk pursuant to a definitive supply agreement.

Management Objectives for Fiscal 2018:

The Company has encountered some significant obstacles during the third quarter and year to date of fiscal 2018. First, reduced sales of higher margin liquid product occurred in Europe and the United States, the latter due to predatory pricing in that market. Only recently have some of these sales resumed but it is hoped this will soon return to the levels of prior years. Second, the failure of our long serving main boiler in the third quarter eliminated all production for three plus weeks, though sales levels were mostly maintained through shipping of previously inventoried product. Production is now returning to normal levels and thankfully without the loss of a single customer.

At this point the order book remains strong and we are looking forward to an exciting fourth quarter, though of course this cannot be guaranteed.

POLYDEX PHARMACEUTICALS LIMITED
 QUARTERLY REPORT
 OCTOBER 31, 2017
 UNAUDITED

Results of Operations

Nine and three months ended October 31, 2017 compared to nine and three months ended October 31, 2016:

	Three Months Ended October 31, 2017	Three Months Ended October 31, 2016	Variance	Nine Months Ended October 31, 2017	Nine Months Ended October 31, 2016	Variance
Net Income	\$233,731	\$244,256	(4%)	\$362,795	\$601,000	(39%)
Net Income per Share						
Basic:	\$0.07	\$0.07		\$0.11	\$0.18	
Diluted:	\$0.07	\$0.07		\$0.10	\$0.17	

The decrease in net income for the third quarter of fiscal 2018 compared to the third quarter of fiscal 2017 is due to decreased sales margins and foreign exchange variations, partially offset by decreased general and administration expenses and deferred income tax expenses. The decrease in net income for the year to date of fiscal 2018 compared to the year to date of fiscal 2017 is due to decreased sales and sales margins, also partially offset by decreased general and administration expenses and deferred income tax expenses.

	Three Months Ended October 31, 2017	Three Months Ended October 31, 2016	Variance	Nine Months Ended October 31, 2017	Nine Months Ended October 31, 2016	Variance
Sales	\$1,434,587	\$1,447,510	(1%)	\$3,969,294	\$4,642,861	(15%)

Sales during the third quarter of fiscal 2018 were consistent with sales levels experienced in the third quarter of fiscal 2017. However year to date sales for the third quarter were impacted by decreased demand for liquid product in the United States and Europe.

POLYDEX PHARMACEUTICALS LIMITED
 QUARTERLY REPORT
 OCTOBER 31, 2017
 UNAUDITED

	Three Months Ended October 31, 2017	Three Months Ended October 31, 2016	Variance	Nine Months Ended October 31, 2017	Nine Months Ended October 31, 2016	Variance
Gross Profit	\$336,031	\$412,705	(19)%	\$921,562	\$1,402,260	(34%)
Percentage of sales	23.4%	28.5%		23.2%	30.2%	

Gross margin percentages in the third quarter and year to date of fiscal 2018 decreased compared to the prior fiscal periods due to plant production issues and significantly decreased sales of higher margin liquid product in the United States and Europe. Boiler replacement in the third quarter interrupted product production for approximately three weeks, while liquid product sales in the United States were reduced to only one shipment for the year to date.

	Three Months Ended October 31, 2017	Three Months Ended October 31, 2016	Variance	Nine Months Ended October 31, 2017	Nine Months Ended October 31, 2016	Variance
Selling, promotion, general and administrative expenses	\$158,734	\$191,900	(17%)	\$480,606	\$574,759	(16%)

These expenses decreased primarily due to decreased legal costs along with reductions to most other administration costs compared to the third quarter and year to date of the prior fiscal year.

	Three Months Ended October 31, 2017	Three Months Ended October 31, 2016	Variance	Nine Months Ended October 31, 2017	Nine Months Ended October 31, 2016	Variance
Research and Development expenditures	\$ --	\$ --	-- %	\$ 600	\$ 600	23%

The Company is maintaining a minimal level of research and development, while concentrating on expanding its customer base with derivatives of existing products. Research and development is consisting solely of legal fees necessary to maintain its cellulose patents.

POLYDEX PHARMACEUTICALS LIMITED
 QUARTERLY REPORT
 OCTOBER 31, 2017
 UNAUDITED

	Three Months Ended October 31, 2017	Three Months Ended October 31, 2016	Variance	Nine Months Ended October 31, 2017	Nine Months Ended October 31, 2016	Variance
Depreciation and amortization expense	\$64,216	\$55,109	17%	\$181,644	\$161,607	12%

Depreciation and amortization increased for the three months and nine months ending October 31 2017 compared to the three and nine months ended October 31, 2016. This was due to the substantial increase in assets acquired in the third quarter of fiscal 2017, especially the purchase of a replacement boiler. Depreciation on the portion of the building that was incurred for the year to date of fiscal 2017, compared to only the third quarter of fiscal

Included in depreciation and amortization expense are allocations to cost of goods sold in the amount of \$175,935 for fiscal year to date 2018 (2017 - \$155,515).

	Three Months Ended October 31, 2017	Three Months Ended October 31, 2016	Variance	Nine Months Ended October 31, 2017	Nine Months Ended October 31, 2016	Variance
Interest Expense	\$8,331	\$9,235	(10)%	\$25,239	\$29,015	(13%)

Interest expense decreased in the third quarter and year to date of fiscal year 2018 compared to 2017 due to the decrease in long term debts as the Company continues to meet its debt repayment commitments.

POLYDEX PHARMACEUTICALS LIMITED
 QUARTERLY REPORT
 OCTOBER 31, 2017
 UNAUDITED

	Three Months Ended October 31, 2017	Three Months Ended October 31, 2016	Variance	Nine Months Ended October 31, 2017	Nine Months Ended October 31, 2016	Variance
Foreign exchange (gain) loss	\$(65,148)	\$(91,322)	(29)%	\$ 18,779	\$20,178	7%

The third quarter and year to date of fiscal 2018 includes a onetime adjustment of approximately \$82,000 related to the amalgamation that reduced the Company's Canadian division's exposure to the United States dollar. Future foreign exchange gains or losses will incorporate only those assets and liabilities to which the Canadian division is exposed.

The foreign exchange gain in the third quarter of fiscal 2017 was due primarily to the decrease in value of the Canadian dollar compared to the United States dollar during the period, while the loss for the year to date in fiscal 2017 was attributable primarily to fluctuations in exchange rates throughout the period.

	Three Months Ended October 31, 2017	Three Months Ended October 31, 2016	Variance	Nine Months Ended October 31, 2017	Nine Months Ended October 31, 2016	Variance
Interest and investment income	\$1,074	\$455		\$3,860	\$1,647	57%
Gain on disposal of equipment	1,150	---		1,150	---	
Interest and other income	\$2,224	\$455	389%	\$5,010	\$1,647	204%

Interest and investment income fluctuates depending on the timing of dividend reinvestments declared that are related to the two investments held by the Company, as well as variations in their market values and exchange rates. During the third quarter of fiscal 2018 the Company purchased a new truck and disposed of a fully depreciated truck, resulting in the gain shown above.

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
OCTOBER 31, 2017
UNAUDITED

Liquidity and Capital Resources

As of October 31, 2017, the Company had cash of \$557,182 compared to cash of \$653,214 at January 31, 2017. In the third quarter of fiscal year 2018, the Company generated cash of \$175,212 in its operating activities, compared to generating cash of \$630,285 for the third quarter of fiscal year 2017. The decrease in cash generation in the third quarter of fiscal 2018 was significantly due to decreased sales margins and lowered sales of liquid product mentioned above. Cash will increase with the receipt of financing related to the cost of the new boiler.

The Company's working capital increased to \$2,632,200 and a working capital ratio of 3.86 to 1 as of October 31, 2017, compared to \$2,459,774 and 3.15 to 1 as of January 31, 2017.

As of October 31, 2017, the Company had accounts receivable of \$1,272,597 and inventory of \$1,051,135 compared to \$1,103,759 and \$1,157,574 respectively at January 31, 2017 and \$735,043 and \$1,146,717 respectively at October 31, 2016. The increase in accounts receivable is primarily due to the timing of customer payments.

At October 31, 2017, the Company had accounts payable of \$420,970 compared to \$443,717 at January 31, 2017 and \$725,138 at October 31, 2016. Accounts payable at October 31, 2017 is comparable to January 31, 2017.

Earnings before interest, taxes, depreciation and amortization (EBITDA) decreased to \$603,122 for the nine months ended October 31, 2017 compared to \$963,885 for the nine months ended October 31, 2016. This decrease is primarily due to production interruption related to the new boiler installation and decreased liquid product sales noted previously.

During the third quarter of fiscal year 2018, capital expenditures amounted to \$243,312 compared to \$90,103 in the third quarter of fiscal year 2017. Capital expenditures are not expected to be as significant as the year to date for the remainder of fiscal year 2018.

The change in accumulated other comprehensive income of the Company is primarily attributable to the currency translation adjustment of the Company's Dextran Products division. Dextran Products' functional currency is the Canadian dollar. This currency translation adjustment arises from the translation of Dextran Products' divisional statements to U.S. dollars.

The decrease in capital lease obligations from January 31, 2017 is due to continued repayments of principal and interest throughout the period.

Changes in the relative values of the Canadian dollar and the United States dollar occur from time to time and may, in certain instances, materially affect the Company's results of operations.

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
OCTOBER 31, 2017
UNAUDITED

The Company does not believe that the impact of inflation has had a material effect on its operations or financial results at any time in the last three years.

Related Party Transactions

In August 1997, the Company loaned the late Thomas C. Usher, its Vice-Chairman, Director of Research and Development, a member of its Board of Directors and the beneficial owner of greater than 5% of the outstanding common shares of the Company, \$691,500 at an interest rate equal to the prime rate of Toronto Dominion Bank plus 1.50% (the "Loan"). The amount outstanding under the Loan as of October 31, 2017 was \$263,285, as compared to \$252,533 at January 31, 2017, including accrued interest. The Company has taken a cumulative provision of \$492,382 at October 31, 2016 (January 31, 2017 - \$481,630) against accrued interest on the Loan and the other amounts receivable from the estate as noted below. Obligations with respect to the Loan transferred to the estate of Thomas C. Usher upon his death in February 2005.

Thomas C. Usher also owed \$250,000 to a subsidiary of the Company, Novadex International Limited, as of October 31, 2017, pursuant to a non-interest bearing loan with no specific repayment terms. The outstanding amount of this loan has not changed from January 31, 2017. The amounts continue to remain owing from the estate of Thomas C. Usher.

As of October 31, 2017, Thomas C. Usher, now through his estate, had pledged 243,263 common shares of the Company as security for these amounts owing to the Company. These common shares had a market value of \$294,348 at October 31, 2017, based on the closing price of the Company's common shares on the Pink Sheets quotation service on October 31, 2017. The Company intends to continue to hold the pledged assets as collateral until the amounts owing discussed above are repaid.

The Company had a commitment to pay an amount equal to one year's salary, \$110,000, to Thomas C. Usher's estate. The amount owing on this commitment as at October 31, 2017 is \$6,962 (January 31, 2017 - \$6,962).

The Company also has an outstanding loan payable to Ruth Usher, a former director and the widow of Thomas C. Usher. The amount due from the Company pursuant to this loan decreased to \$378,613 at October 31, 2017 from \$396,592 at January 31, 2017 due to monthly payments by the Company, less interest charges.

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
OCTOBER 31, 2017
UNAUDITED

Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements.

Critical Accounting Policies

The Company's interim consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States, applied on a consistent basis. The critical accounting policies include the use of estimates of allowance for doubtful accounts, the useful lives of assets and the realizability of deferred tax assets.

Management is required to make estimates and assumptions in preparing the consolidated financial statements that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the periods. The actual results could differ from these estimates. Significant estimates made by management include the calculation of reserves for uncollectible accounts, inventory allowances, useful lives of long-lived assets and the realizability of deferred tax assets.

Revenue Recognition

Revenue results from sales of bulk manufactured products and is recognized when title and risk of ownership of products pass to the customer. Title and risk of ownership pass to the customer pursuant to the applicable sales contract, either upon shipment of product or upon receipt by the customer. Since returns are rare and generally not accepted, management has not made provision for returns. In addition, product sold in bulk quantities is tested, prior to release for shipment, to ensure that it meets customer specifications, and in many cases, customers receive samples for their own testing. Approval is obtained from the customer prior to shipping.

Allowance for Doubtful Accounts

Accounts receivable is stated net of allowances for doubtful accounts. Allowances for doubtful accounts are determined by each reporting unit on a specific item basis. Management reviews the credit worthiness of individual customers and past payment history to determine the allowance for doubtful accounts. Since the majority of sales at Dextran Products are export, Dextran Products maintains credit insurance through a crown corporation which is supported by the Canadian government, for the majority of its customers' receivables. There has been no allowance for doubtful accounts during the past two fiscal years.

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
OCTOBER 31, 2017
UNAUDITED

Long-Lived Assets

Long-lived assets are stated at cost, less accumulated depreciation or amortization computed using the straight-line method based on their estimated useful lives ranging from three to fifteen years. Useful life is the period over which the asset is expected to contribute to the Company's future cash flows. A significant change in estimated useful lives could have a material impact on the results of operations. The Company reviews the recoverability of its long-lived assets, including buildings, equipment and other intangible assets, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on the Company's ability to recover the carrying value of the asset from the expected future pre-tax cash flows of the related operations. If these cash flows are less than the carrying value of such asset, an impairment loss is recognized for the difference between estimated fair value and carrying value. The measurement of impairment requires management to make estimates of these cash flows related to long-lived assets as well as other fair value determinations.

Deferred Tax Assets

The Company has recorded a valuation allowance on deferred tax assets where there is uncertainty as to the ultimate realization of the future tax deduction. Dextran Products has incurred capital losses, which are only deductible against capital gains. It is not certain that Dextran Products will realize capital gains in the future to use these Canadian capital loss deductions.

Changes in Accounting Policies

No changes in accounting principles or their application have been implemented in the reporting period that would have a material effect on reported income.

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
OCTOBER 31, 2017
UNAUDITED

ITEM V LEGAL PROCEEDINGS

An employee of the Company's subsidiary, Dextran Products Limited, has filed a claim alleging improper termination and harassment. The Company has engaged legal counsel and discussions are ongoing.

ITEM VI DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM VII OTHER INFORMATION

Not applicable.

ITEM VIII EXHIBITS

Not applicable

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
OCTOBER 31, 2017
UNAUDITED

ITEM IX CERTIFICATIONS

I, George G. Usher, certify that:

1. I have reviewed this quarterly disclosure statement of Polydex Pharmaceuticals Limited;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

December 15, 2017

/s/ George G. Usher

Chairman, President and Chief Executive Officer
Polydex Pharmaceuticals Limited

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
OCTOBER 31, 2017
UNAUDITED

ITEM IX CERTIFICATIONS (Continued)

I, John A. Luce, certify that:

1. I have reviewed this quarterly disclosure statement of Polydex Pharmaceuticals Limited;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

December 15, 2017

/s/ John A. Luce

Chief Financial Officer
Polydex Pharmaceuticals Limited